Date / Time
The goal of this activity is to improve the knowledge and competence of learners to integrate emerging and innovative therapies for ITP.
This program is intended for global physicians and other healthcare professionals who care for patients with ITP.
Upon completion of this activity, participants should be able to:
- Describe recent advances in the understanding of immune thrombocytopenia pathophysiology that have led to the development of new targeted therapies
- Identify the mechanism of action of novel targeted therapies that are being tested for patients with immune thrombocytopenia
- Evaluate the available efficacy and safety data for novel targeted therapies in patients with immune thrombocytopenia
- Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this activity is 1.0 contact hour.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.